Mobile Lung Cancer Screening in Limited Resource Regions: The ProPulmão Project (BRELT3) Study Protocol - dos Santos, Ricardo Sales; Figueiredo, Ricardo; Franceschini, Juliana P.; de Araújo Neto, César Augusto; Machado, Almério; Hochhegger, Bruno; Ghefter, Mario Claudio; Pereira Neto, Ulisses Amancio; Sarmento, Petrucio Abrantes; Ribeiro, Igor Barbosa; Xavier Carvalho, Daniel Augusto; Passos, Felipe; et al. (medRxiv, 2024)
Background Lung cancer is a highly aggressive disease that affected almost 2.2 million people worldwide and caused 1.8 million deaths in 2020. Smoking as well as being exposed to cancer-causing substances in the workplace are significant contributors to the chance of developing cancer. Developing countries encounter distinctive obstacles in the implementation of lung cancer screening because of extensive geographical and socioeconomic disparities.Objectives our primary objective is to describe tomographic findings in a high-risk lung cancer population in limited resource Brazilian areas. The secondary objectives are to quantify the frequency of pulmonary nodules (especially those falling into Lung-RADS categories 3 and 4) as well as the occurrence of lung cancer; to describe and analyze the challenges related to lung cancer screening programs in the context of Brazilian public health system; to explain the pulmonary function pattern and clinical characteristics of individuals diagnosed with moderate or severe emphysema by low-dose computed tomography (LDCT); and to evaluate the commitment of Community Health Assistants in actively recruiting the high-risk population.Methods This is a prospective cohort study. The study includes individuals in an age range of 50 to 80 years who are either current or former smokers and have a smoking history of at least 20 pack-years. They undergo LDCT with a planned follow up of 12 months. All adverse events are monitored and assisted. The classification of screening results is performed according to the Lung-RADS standards. Individuals classified in categories 3 and 4 receive additional diagnostic assessments and may have further testing.Expected results we expect this study shows the feasibility and effectiveness of lung cancer screening in people in situation of social vulnerability within limited resource settings, providing vital knowledge to reduce mortality and improve health outcomes. The project will generate relevant knowledge to inform policies on lung cancer screening within the Brazilian public health system, emphasizing the necessity of timely identification and action in limited resource settings.Outcome The study’s dissemination plan includes a website, social media, and participation in scientific conferences. Approval from the ethics committee has been obtained, and rigorous mechanisms are in place to guarantee the privacy of the data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received financial support from the Bristol-Myers Squibb Foundation for the development of the mobile unit and LDCTs, Boehringer Ingelheim Brazil for spirometry, Diagnósticos da América S.A. (DASA) for CT reports, AstraZeneca Brazil & Lung Ambition Alliance for educational activities and Ethicon Brazil and Panther Brazil for medical devices.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the SENAI-CIMATEC Institutional Review Board through a CAAE number 67431523.6.0000.9287.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.